InvestorsHub Logo
Post# of 252301
Next 10
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

Re: Biowatch post# 33611

Thursday, 09/07/2006 8:23:32 AM

Thursday, September 07, 2006 8:23:32 AM

Post# of 252301
GTCB – This settlement indirectly affects GTC because GTC licensed its nuclear-transfer technology from ACTC. Thus, GTC may now owe certain royalties to stART Licensing (the JV of GERN and Exeter) instead of to ACTC, but this shouldn’t make any real difference.

Importantly, this outcome does not affect GTC’s lead, drug, ATryn, because the goat herd for ATryn was created using microinjection rather than nuclear transfer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.